New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
09:45 EDTENTA, ENTA, ENTAEnanta Pharmaceuticals has a conference call hosted by JPMorgan
JPMorgan Analysts Meacham and Kasimov will host a conference call with CEO Jay Luly on February 28 at 10 am.
News For ENTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2015
13:14 EDTENTAEnanta says 34 abstracts from AbbVie chronic hep C program to be presented
Subscribe for More Information
September 28, 2015
06:02 EDTENTAEnanta announces approval of Viekirax in Japan
Enanta announced that the Japanese Ministry of Health, Labour and Welfare approved AbbVie's VIEKIRAX, as a new interferon-free and ribavirin-free treatment option for adult patients in Japan with chronic genotype 1 hepatitis C virus infection, including those with compensated liver cirrhosis.1 VIEKIRAX consists of two-direct-acting antiviral, fixed-dose tablets containing paritaprevir/ritonavir with ombitasvir. VIEKIRAX is approved in Japan using once daily dosing for 12 weeks for GT1 HCV patients. Enanta expects to earn and receive a $30 million milestone payment in the quarter ending December 31, 2015 upon price reimbursement approval of VIEKIRAX in Japan. In addition, forty five percent of AbbVie's net sales of the 2-DAA regimen in Japan will be included in the worldwide paritaprevir net sales on which Enanta is eligible to receive annually tiered royalties, ranging from the low double digits up to twenty percent. AbbVie is responsible for all worldwide development and commercialization of VIEKIRAX and other HCV treatment regimens containing paritaprevir. Paritaprevir/ritonavir and ombitasvir, AbbVie's NS5A inhibitor, are also included in AbbVie's 3-DAA VIEKIRA PAK regimen, which was approved in the U.S. in late 2014 for patients with GT1 HCV infection. VIEKIRAX was first approved under that name in Europe in January 2015.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use